NASDAQ:LNTH Lantheus (LNTH) Stock Forecast, Price & News $69.64 +0.11 (+0.16%) (As of 03:28 PM ET) Add Compare Share Share Today's Range$68.44▼$70.4450-Day Range$60.27▼$87.9552-Week Range$47.46▼$100.85Volume722,924 shsAverage Volume1.02 million shsMarket Capitalization$4.77 billionP/E Ratio169.85Dividend YieldN/APrice Target$119.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Lantheus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.9% Upside$119.33 Price TargetShort InterestBearish7.48% of Float Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.71Based on 8 Articles This WeekInsider TradingSelling Shares$1.54 M Sold Last QuarterProj. Earnings Growth7.71%From $5.19 to $5.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.43 out of 5 starsMedical Sector136th out of 972 stocksDiagnostic Substances Industry3rd out of 13 stocks 3.5 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.33, Lantheus has a forecasted upside of 71.9% from its current price of $69.44.Amount of Analyst CoverageLantheus has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.48% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Lantheus has recently decreased by 3.65%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 2.6 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Lantheus this week, compared to 5 articles on an average week.Search Interest21 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,542,833.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 7.71% in the coming year, from $5.19 to $5.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 169.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 169.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 120.68.Price to Book Value per Share RatioLantheus has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantheus (NASDAQ:LNTH) StockLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesSeptember 28, 2023 | benzinga.comLooking At Lantheus Holdings's Recent Unusual Options ActivitySeptember 27, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Buy" from BrokeragesSeptember 29, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 21, 2023 | finance.yahoo.comWall Street Bulls Look Optimistic About Lantheus Holdings (LNTH): Should You Buy?September 5, 2023 | finance.yahoo.comWall Street Analysts Think Lantheus Holdings (LNTH) Is a Good Investment: Is It?September 1, 2023 | finance.yahoo.comLantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual MeetingAugust 30, 2023 | seekingalpha.comLantheus: Growth Well Priced In, Profitability Next Hurdle (Rating Downgrade)August 30, 2023 | seekingalpha.comLantheus: Not Quite Ready To Take The PlungeSeptember 29, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 19, 2023 | money.usnews.comLantheus Holdings IncAugust 18, 2023 | seekingalpha.comLantheus to discontinue radiotherapy AzedraAugust 8, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Lantheus (LNTH)August 7, 2023 | markets.businessinsider.comLantheus (LNTH) Receives a Buy from Truist FinancialAugust 4, 2023 | finance.yahoo.comLantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | finance.yahoo.comShould You Be Concerned About Lantheus Holdings, Inc.'s (NASDAQ:LNTH) ROE?August 4, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on Lantheus (LNTH)August 3, 2023 | benzinga.comLantheus Holdings Unusual Options Activity For August 03August 3, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Lantheus (LNTH)August 3, 2023 | seekingalpha.comLantheus Holdings, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 3, 2023 | washingtonpost.comLantheus Holdings: Q2 Earnings SnapshotAugust 3, 2023 | finance.yahoo.comLantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare RoyaltyAugust 3, 2023 | finance.yahoo.comLantheus Holdings (LNTH) Surpasses Q2 Earnings and Revenue EstimatesJuly 28, 2023 | finance.yahoo.comLantheus (LNTH) to Report Q2 Earnings: What's in the Cards?July 23, 2023 | markets.businessinsider.comTruist Financial Remains a Buy on Lantheus (LNTH)July 20, 2023 | finance.yahoo.comLantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern TimeJuly 17, 2023 | markets.businessinsider.comLantheus (LNTH) Gets a Buy from Truist FinancialJuly 12, 2023 | finance.yahoo.comIs It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views?See More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Company Calendar Last Earnings8/03/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees698Year FoundedN/APrice Target and Rating Average Stock Price Forecast$119.33 High Stock Price Forecast$130.00 Low Stock Price Forecast$104.00 Forecasted Upside/Downside+71.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio169.59 Forward P/E Ratio13.40 P/E GrowthN/ANet Income$28.07 million Net Margins2.97% Pretax Margin1.72% Return on Equity67.18% Return on Assets27.42% Debt Debt-to-Equity Ratio1.01 Current Ratio4.88 Quick Ratio4.55 Sales & Book Value Annual Sales$935.06 million Price / Sales5.09 Cash Flow$5.04 per share Price / Cash Flow13.79 Book Value$6.50 per share Price / Book10.70Miscellaneous Outstanding Shares68,430,000Free Float67,405,000Market Cap$4.76 billion OptionableOptionable Beta0.68 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Mary Anne Heino (Age 63)CEO & Director Comp: $2.23MMr. Paul M. Blanchfield (Age 42)Pres Comp: $962.41kMr. Robert J. Marshall Jr. (Age 56)CFA, CFO & Treasurer Comp: $1.06MMr. Daniel M. Niedzwiecki (Age 46)Chief Admin. Officer, Gen. Counsel & Corp. Sec. Comp: $871.93kMr. Etienne Montagut (Age 48)Chief Bus. Officer Comp: $789.15kMs. Andrea Sabens (Age 44)Chief Accounting Officer Ms. Dorothy BarrSr. VP of Manufacturing & Technical OperationsMr. Mark Richard KinarneySr. Director of Investor RelationsMs. Linda S. Lennox (Age 57)VP of Corp. Communications & Chief of Staff Ms. Carol Walker (Age 60)Sr. VP of Quality More ExecutivesKey CompetitorsQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInsiders & InstitutionsDaniel NiedzwieckiSold 2,846 sharesTotal: $189,059.78 ($66.43/share)Prosperity Financial Group Inc.Bought 180 shares on 9/12/2023Ownership: 0.004%Portside Wealth Group LLCBought 64,848 shares on 9/1/2023Ownership: 0.095%Wolverine Trading LLCBought 17,000 shares on 8/23/2023Ownership: 0.000%Comerica BankBought 75,956 shares on 8/22/2023Ownership: 0.111%View All Insider TransactionsView All Institutional Transactions LNTH Stock - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price forecast for 2023? 5 equities research analysts have issued 1 year price targets for Lantheus' stock. Their LNTH share price forecasts range from $104.00 to $130.00. On average, they anticipate the company's stock price to reach $119.33 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2023? Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH stock has increased by 36.4% and is now trading at $69.53. View the best growth stocks for 2023 here. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, August, 3rd. The medical equipment provider reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.17. The medical equipment provider had revenue of $321.70 million for the quarter, compared to analyst estimates of $306.48 million. Lantheus had a trailing twelve-month return on equity of 67.18% and a net margin of 2.97%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Harbor Small Cap Explorer ETF (QWST), American Century Mid Cap Growth Impact (MID), Invesco S&P MidCap 400 Pure Growth ETF (RFG), First Trust Active Factor Small Cap ETF (AFSM) and SoFi Next 500 ETF (SFYX). What guidance has Lantheus issued on next quarter's earnings? Lantheus updated its third quarter 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $1.30-$1.35 for the period, compared to the consensus earnings per share estimate of $1.37. The company issued revenue guidance of $310.00 million-$315.00 million, compared to the consensus revenue estimate of $316.89 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $69.53. How much money does Lantheus make? Lantheus (NASDAQ:LNTH) has a market capitalization of $4.76 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or $0.41 on an earnings per share basis. How many employees does Lantheus have? The company employs 698 workers across the globe. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860. This page (NASDAQ:LNTH) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.